Myriad Genetics, Inc. (MYGN) Insider Sells $95,900.84 in Stock

Myriad Genetics, Inc. (NASDAQ:MYGN) insider Alexander Ford sold 3,031 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $31.64, for a total value of $95,900.84. The sale was disclosed in a filing with the SEC, which is available through this link.

Myriad Genetics, Inc. (MYGN) opened at $33.41 on Friday. The company has a market cap of $2,163.77, a PE ratio of 28.67, a P/E/G ratio of 1.98 and a beta of 0.24. Myriad Genetics, Inc. has a fifty-two week low of $15.15 and a fifty-two week high of $37.30. The company has a current ratio of 2.34, a quick ratio of 2.06 and a debt-to-equity ratio of 0.09.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.05. Myriad Genetics had a net margin of 13.28% and a return on equity of 9.54%. The firm had revenue of $190.20 million during the quarter, compared to analysts’ expectations of $183.52 million. During the same quarter in the prior year, the company earned $0.23 EPS. The company’s revenue was up 7.2% compared to the same quarter last year. equities analysts predict that Myriad Genetics, Inc. will post 1.05 earnings per share for the current fiscal year.

WARNING: This story was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://ledgergazette.com/2017/11/17/myriad-genetics-inc-mygn-insider-sells-95900-84-in-stock-4.html.

A number of equities analysts have recently weighed in on the company. BidaskClub downgraded Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Barclays PLC dropped their target price on Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $23.00 price target (up previously from $21.00) on shares of Myriad Genetics in a report on Thursday, August 10th. Zacks Investment Research cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Finally, Cowen and Company reissued a “hold” rating and issued a $25.00 target price on shares of Myriad Genetics in a research note on Monday, August 14th. Two analysts have rated the stock with a sell rating, seven have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $28.10.

Institutional investors have recently modified their holdings of the business. SG Americas Securities LLC acquired a new stake in Myriad Genetics during the second quarter valued at $101,000. Riverhead Capital Management LLC grew its position in Myriad Genetics by 80.9% during the second quarter. Riverhead Capital Management LLC now owns 4,161 shares of the company’s stock valued at $107,000 after buying an additional 1,861 shares during the period. Fiduciary Trust Co. purchased a new position in Myriad Genetics during the second quarter valued at $113,000. Meeder Asset Management Inc. lifted its holdings in Myriad Genetics by 1,067.4% during the third quarter. Meeder Asset Management Inc. now owns 3,292 shares of the company’s stock valued at $119,000 after purchasing an additional 3,010 shares in the last quarter. Finally, Tiedemann Wealth Management LLC lifted its holdings in Myriad Genetics by 67.0% during the third quarter. Tiedemann Wealth Management LLC now owns 13,650 shares of the company’s stock valued at $185,000 after purchasing an additional 5,475 shares in the last quarter.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply